EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity

Caterina Musolino, Alessandro Allegra, Carmen Mannucci, Sabina Russo, Andrea Alonci, Valerio Maisano, Gioacchino Calapai, Sebastiano Gangemi

Turkish Journal of Hematology · 05.06.2015 · 32 (2) · 168-171

DOI: 10.4274/tjh.2014.0021 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Turkish Journal of Hematology, online erschienen am 05.06.2015. Verfasst von Caterina Musolino und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Messina Faculty of Medicine, Department of General Surgery and Oncology, Division of Hematology, Messina, Italy Phone: 0039 090 221 23 …. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent. The aim of this work was to investigate the possible contribution of interleukin (IL)-33 and IL-31, cytokines involved in disorders associated with itching, in the pathogenesis of pruritus in a patient undergoing imatinib mesylate treatment. His IL-31 and IL-33 serum levels were significantly higher than in the control group (respectively 96.6 pg/mL vs. 7.623±7.681 pg/mL and 27.566 pg/mL vs. 6.170±7.060 pg/mL). In light of these findings, imatinib mesylate-related symptoms of dermatologic toxicities might be related to the release of IL-31 and IL-33. In particular, it is supposable that TKi usage could cause keratinocyte injury, the release of IL-33, and the consequent interaction with its receptor on mast cells that induces the secretion of several factors capable of causing skin manifestations, including IL-31, a known pruritus-inducing cytokine. This report, to the best of our knowledge, is the first work describing the possible involvement of the IL-31/IL-33 axis in the pathogenesis of skin side effects related to imatinib mesylate treatment. İmatinib mesilat c-ABL ve BCR-ABL’yi hedeflemek için tasarlanan küçük- molekül tirozin kinaz inhibitörü (TKİ) olup kronik miyeloid lösemi ve gastrointestinal stromal tümör tedavisi için onaylanmıştır. İmatinib ile indüklenen advers kutanöz reaksiyonlar nadir, genellikle ılımlı ve doz bağımlıdır. Bu çalışmanın amacı, kaşıntı ile ilişkili bozukluklar ile ilgili sitokinler olan interlökin (IL)-33 ve IL-31’in imatinib mesilat tedavisi alan bir hastada kaşıntı patogenezine olası katkısını araştırmak idi. Hastanın serum IL-31 ve IL-33 düzeyleri kontrol grubundan anlamlı olarak yüksek idi (sırasıyla; 96,6 pg/mL vs. 7,623±7,681 pg/mL ve 27,566 pg/mL vs. 6,170±7,060 pg/mL). Bu bulgular ışığında, imatinib mesilat- ile ilişkili dermatolojik toksisiteler IL-31 ve IL-33 salınımı ile ilişkili olabilir. Özellikle, TKİ kullanımının keratinosit hasarı, IL-33 salınımı ve mast hücre yüzeyindeki reseptörü ile karşılıklı etkileşimi sonucu, deri bulgularına yol açma yeteneği olan, kaşıntıyı-indükleyen bir sitokin olarak bilinen IL-31’de içeren çeşitli faktörlerin sekresyonuna sebep olabileceği varsayılabilir. Bu rapor, bildiğimizce, imatinin mesilat tedavisi ile ilişkili deri yan etkilerinin patogenezinde interlökin-31/33 aksının olası rolünü tanımlayan ilk çalışmadır.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgedAntineoplastic AgentsDrug EruptionsHumansImatinib MesylateInterleukin-1 Receptor-Like 1 ProteinInterleukin-33InterleukinsKeratinocytesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMast CellsProtein Kinase InhibitorsPruritus

Substanzen

Antineoplastic AgentsIL1RL1 protein, humanIL31 protein, humanIL33 protein, humanInterleukin-1 Receptor-Like 1 ProteinInterleukin-33InterleukinsProtein Kinase InhibitorsImatinib Mesylate

Autor:innen und Institutionen

  • University of Messina Faculty of Medicine, Department of General Surgery and Oncology, Division of Hematology, Messina, Italy Phone: 0039 090 221 23 64 E-mail: aallegra@unime.it.

Zitieren

APA

Musolino, C., Allegra, A., Mannucci, C., Russo, S., Alonci, A., Maisano, V., Calapai, G., & Gangemi, S. (2015). Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity. Turkish Journal of Hematology, 32(2), 168-171. https://doi.org/10.4274/tjh.2014.0021

Vancouver

Musolino C, Allegra A, Mannucci C, Russo S, Alonci A, Maisano V, et al. Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity. Turkish Journal of Hematology. 2015;32(2):168-171. doi:10.4274/tjh.2014.0021

BibTeX
@article{Musolino2015,
  author = {Musolino, Caterina and Allegra, Alessandro and Mannucci, Carmen and Russo, Sabina and Alonci, Andrea and Maisano, Valerio and Calapai, Gioacchino and Gangemi, Sebastiano},
  title = {Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity},
  journal = {Turkish Journal of Hematology},
  year = {2015},
  volume = {32},
  number = {2},
  pages = {168--171},
  doi = {10.4274/tjh.2014.0021}
}
Kostenlos starten →